The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.
 
Celestia S. Higano
Employment - CTI (I)
Leadership - CTI (I)
Stock and Other Ownership Interests - CTI (I)
Honoraria - Genentech
Consulting or Advisory Role - Asana Biosciences; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Dendreon; Endocyte; Ferring; Myriad Genetics; Orion; Tolmar
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Asana Biosciences; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Dendreon; Endocyte; Ferring; Genentech; Menarini; Myriad Genetics; Orion; Pfizer
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology; Sanofi
Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Sanofi
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Bayer; Dendreon; Janssen Biotech; Medivation; Sanofi
 
A. Oliver Sartor
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Oncogenex; Pfizer; Sanofi
Research Funding - Bayer (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Johnson & Johnson (Inst); Merck; Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bellicum Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Progenics; Sanofi; Tokai Pharmaceuticals
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Context Therapeutics; Druggablity Technologies; Placon; Seer; Tarveda Therapeutics
Consulting or Advisory Role - Bavarian Nordic; BIND Biosciences; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; Metamark Genetics; New England Research Institutes; OncoCellMDX; Progenity; Sanofi; Seer; Tarveda Therapeutics; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen
Travel, Accommodations, Expenses - Sanofi
 
David G. McLeod
No Relationships to Disclose
 
Christopher Michael Pieczonka
Consulting or Advisory Role - Astellas Pharma; Dendreon; Janssen
Speakers' Bureau - Astellas Pharma; Dendreon; Janssen
Research Funding - Astellas Pharma; Bayer; Dendreon; Janssen
 
David F. Penson
Consulting or Advisory Role - Astellas Pharma; Dendreon; Janssen
Research Funding - Astellas Pharma (Inst)
 
Neal D. Shore
Leadership - Large Urology Group Practice Association
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Sanofi; Tolmar
 
Jeffrey L. Vacirca
Leadership - Odonate Therapeutics
Stock and Other Ownership Interests - Flatiron Health; Odonate Therapeutics
Consulting or Advisory Role - AmerisourceBergen
 
Raoul S Concepcion
Consulting or Advisory Role - Genomic Health; IntegraConnect
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; Dendreon; Janssen Oncology; Sanofi
 
Ronald F Tutrone
Stock and Other Ownership Interests - Novartis; Nymox; Sophiris Bio
Consulting or Advisory Role - 3D Biopsy; Medivation/Astellas; Pfizer
Speakers' Bureau - Dendreon; Medivation/Astellas
Research Funding - Advaxis (Inst); Allena Pharmaceuticals (Inst); Allergan (Inst); American Medical Systems (Inst); Bayer (Inst); Boston Scientific (Inst); Genentech/Roche (Inst); Genomic Health (Inst); Janssen Oncology (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Mundipharma (Inst); Neotract (Inst); Nymox (Inst); Sophiris Bio (Inst)
 
Luke T. Nordquist
No Relationships to Disclose
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Vahan Kassabian
Stock and Other Ownership Interests - UROGPO; Valeant Pharmaceuticals International
Honoraria - Amgen; Astellas Pharma; Bayer; Dendreon; Genomic Health; Janssen; Tolmar
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Genomic Health; Janssen; Tolmar
Research Funding - Dendreon
 
Mark C. Scholz
Honoraria - Astellas Pharma (I); Dendreon (I); Pfizer (I)
Consulting or Advisory Role - Astellas Pharma (Inst); Dendreon (Inst); Janssen (Inst); Pfizer (Inst)
Speakers' Bureau - Astellas Pharma (I); Dendreon (I); Janssen (I); Pfizer (I)
Research Funding - Dendreon
Travel, Accommodations, Expenses - Astellas Pharma; Dendreon; Janssen; Pfizer
 
Robert C. Tyler
Employment - Dendreon
 
Nancy N. Chang
Employment - Dendreon
Stock and Other Ownership Interests - Dendreon
 
Bruce Brown
Employment - Dendreon
 
Matthew R. Cooperberg
Honoraria - GenomeDx; Takeda
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; MDxHealth; Myriad Pharmaceuticals
Research Funding - GenomeDx (Inst); Genomic Health (Inst); Myriad Pharmaceuticals (Inst)